Business Context and Reporting Period
This Form 8-K was filed by pSivida Limited on March 14, 2008, reporting a material definitive agreement entered into on the same date. The filing details an amended and restated license and collaboration agreement between pSivida, Inc. (a wholly owned subsidiary of pSivida Limited) and Alimera Sciences, Inc. regarding Medidur FA, a Phase III investigative treatment for diabetic macular edema (DME).
Key Financial Metrics and Transaction Terms
- Total Consideration: Up to approximately $78 million to pSivida.
- Upfront Cash Payment: $12 million paid by Alimera upon execution.
- Milestone Payment: $25 million payable within 30 days of the first FDA approval of a "First Product."
- Debt Instrument: Alimera issued a Note for $15 million, payable upon a liquidity event generating at least $75 million in aggregate proceeds prior to September 30, 2012.
- Profit Sharing: Alimera's share of future Net Profits increased from 50% to 80%; pSivida retains 20%.
- Debt Settlement: Approximately $5.3 million (including penalties and interest) previously owed by pSivida to Alimera was deemed fully paid as of March 14, 2008.
- Note Interest Rate: 8% per annum until March 31, 2010, increasing to 20% per annum thereafter.
Material Changes Versus Prior Period
The Restated Agreement significantly alters the financial and operational structure of the original 2005 collaboration:
- Profit Split Adjustment: pSivida's share of Net Profits decreased from 50% to 20%, while Alimera's share increased to 80%.
- R&D Responsibility: Alimera assumed full financial responsibility and control for the research and development of licensed products, whereas pSivida retains limited development obligations for Medidur FA only until December 31, 2009.
- Commercialization Control: Alimera maintains sole responsibility for commercialization in the United States, European Union, and Japan.
- Debt Obligation: The transaction introduced a new $15 million Note payable upon specific liquidity events, replacing previous outstanding balances between the parties.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement is designed to accelerate the development and commercialization of Medidur FA by transferring financial risk and operational control to Alimera. pSivida retains a 20% stake in Net Profits and royalties, with potential upside if Alimera fails to meet payment obligations.
Risks and Contingencies:
- Default Provisions (Fifty/Fifty Amendments): If Alimera defaults on interest or scheduled payments, or fails to reimburse development costs, pSivida's share of Net Profits and royalties automatically increases to 50%.
- Termination Rights: pSivida may terminate the agreement if Alimera fails to achieve a liquidity event by September 30, 2012, or commits a "third payment default."
- Note Cancellation: If the agreement is terminated due to a liquidity event failure or third payment default, the $15 million Note is cancelled, and Alimera has no further obligation to pay principal or interest.
- Liquidity Event Dependency: The $15 million Note payment is contingent on Alimera achieving aggregate proceeds of at least $75 million from liquidity events prior to September 30, 2012.
Important Facts for Investor Verification
- Verify the definition of "Net Profits" in the Restated Agreement to understand the actual revenue base for the 20% profit share.
- Confirm the status of Medidur FA's Phase III clinical trials and the likelihood of FDA approval to trigger the $25 million milestone.
- Monitor Alimera's ability to meet the $75 million liquidity event threshold by September 30, 2012, which triggers the $15 million Note payment.
- Review the specific terms of the "Fifty/Fifty Amendments" to assess the risk of Alimera defaulting on payments and the resulting shift in profit distribution.
- Check the upcoming Form 10-Q for the quarter ended March 31, 2008, for the full text of the Restated Agreement.